Trial · NCT03990649
Participant flow18
How many started, completed or left each group, period by period.
1 to 18 of 18
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Part A: DB Treatment Period (15 Weeks) | STARTED | Double-Blind Treatment Period - Part A: Placebo | 9 | |
| Part A: DB Treatment Period (15 Weeks) | STARTED | Double-Blind Treatment Period - Part A: Soticlestat | 15 | |
| Part A: DB Treatment Period (15 Weeks) | STARTED | Open-Label Extension Period - Part B: Soticlestat | 0 | |
| Part A: DB Treatment Period (15 Weeks) | COMPLETED | Double-Blind Treatment Period - Part A: Placebo | 6 | |
| Part A: DB Treatment Period (15 Weeks) | COMPLETED | Double-Blind Treatment Period - Part A: Soticlestat | 12 | |
| Part A: DB Treatment Period (15 Weeks) | COMPLETED | Open-Label Extension Period - Part B: Soticlestat | 0 | |
| Part A: DB Treatment Period (15 Weeks) | NOT COMPLETED | Double-Blind Treatment Period - Part A: Placebo | 3 | |
| Part A: DB Treatment Period (15 Weeks) | NOT COMPLETED | Double-Blind Treatment Period - Part A: Soticlestat | 3 | |
| Part A: DB Treatment Period (15 Weeks) | NOT COMPLETED | Open-Label Extension Period - Part B: Soticlestat | 0 | |
| Part B: OL Extension Period (14 Weeks) | STARTED | Double-Blind Treatment Period - Part A: Placebo | 0 | |
| Part B: OL Extension Period (14 Weeks) | STARTED | Double-Blind Treatment Period - Part A: Soticlestat | 0 | |
| Part B: OL Extension Period (14 Weeks) | STARTED | Open-Label Extension Period - Part B: Soticlestat | 18 | |
| Part B: OL Extension Period (14 Weeks) | COMPLETED | Double-Blind Treatment Period - Part A: Placebo | 0 | |
| Part B: OL Extension Period (14 Weeks) | COMPLETED | Double-Blind Treatment Period - Part A: Soticlestat | 0 | |
| Part B: OL Extension Period (14 Weeks) | COMPLETED | Open-Label Extension Period - Part B: Soticlestat | 14 | |
| Part B: OL Extension Period (14 Weeks) | NOT COMPLETED | Double-Blind Treatment Period - Part A: Placebo | 0 | |
| Part B: OL Extension Period (14 Weeks) | NOT COMPLETED | Double-Blind Treatment Period - Part A: Soticlestat | 0 | |
| Part B: OL Extension Period (14 Weeks) | NOT COMPLETED | Open-Label Extension Period - Part B: Soticlestat | 4 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03990649/flow